Creating new tools for advanced cancer radiation therapy
Development of Novel Heterogeneous Range Modulators for FLASH Particle Therapy
This study is looking at new ways to improve FLASH proton therapy, a special cancer treatment that delivers quick bursts of radiation, to make it work better for patients by targeting tumors more precisely and reducing harm to healthy tissues, which could lead to faster treatments with fewer side effects.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10952781 on NIH RePORTER |
What this research studies
This research focuses on developing novel modulators for FLASH proton therapy, a cutting-edge cancer treatment that uses ultra-high dose rates of radiation. By integrating these modulators with existing proton therapy systems, the goal is to enhance the effectiveness of tumor targeting while minimizing damage to surrounding healthy tissues. The approach involves preclinical studies and clinical trials to understand the biological mechanisms and physical requirements for successful implementation. Patients may benefit from faster and more effective treatments with fewer side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with deep-seated tumors who are undergoing proton therapy.
Not a fit: Patients who do not have cancer or those whose tumors are not suitable for proton therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments with reduced side effects for patients.
How similar studies have performed: Other research has shown promising results with FLASH radiotherapy approaches, indicating potential for significant advancements in cancer treatment.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Teo, Boon-Keng Kevin — University of Pennsylvania
- Study coordinator: Teo, Boon-Keng Kevin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.